Chemo Control

Drugs target epigenetic changes in cancer cells

Join Our Community of Science Lovers!

On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.

Today's cancer chemotherapy consists of little more than a dismal array of toxic drugs that kill healthy cells along with cancerous ones. Physicians must often play a deadly game of trial and error, hoping to find the right dose of the right medicine before time runs out. But a pipeline of new molecular drugs targeting so-called epigenetic phenomena could change that. These treatments could mark a path to a new array of cancer prevention strategies less toxic to the body.

The term "epigenetics" refers to the study of changes in gene expression that do not involve changes in the genetic code; they include an expanding roster of subtle molecular modifications that tell cells which genes to activate (or transcribe) and which to suppress. In cancer cells, these small-molecule regulators can act like broken dimmer switches, turning genes that promote cell growth all the way up and those that suppress tumors all the way down. By comparing the epigenetic patterns of cancerous cells with those of healthy cells, scientists are trying to identify the abnormalities tied to tumor growth. Research has led to the discovery of epigenetic culprits in many cancers, including those found in the colon, prostate, breast and blood.

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American